Horizon Pharma (HZNP)

Add to Watchlists Create an Alert
2.40 +0.01  +0.42%   NASDAQ May 24, 5:00PM BATS Real time Currency in USD

Horizon Pharma R&D Expense Quarterly:

4.739M for Dec. 31, 2012
View Full Chart

Horizon Pharma R&D Expense Quarterly Chart

    Horizon Pharma Historical R&D Expense Quarterly Data

    Pro Data Export
    Dates:  to
    Viewing 1 of 1   First  Previous First    Next  Last   Last

    There is no data for the selected date range.

    Data for this Date Range  
    Dec. 31, 2012 4.739M
    Sept. 30, 2012 3.796M
    June 30, 2012 4.233M
    March 31, 2012 4.069M
    Dec. 31, 2011 3.822M
    Sept. 30, 2011 5.346M
    June 30, 2011 3.462M
    March 31, 2011 2.729M
       
    Dec. 31, 2010 4.836M
    Sept. 30, 2010 5.721M
    June 30, 2010 4.292M
    March 31, 2010 2.826M
    Dec. 31, 2009 3.312M
    Sept. 30, 2009 2.497M
    June 30, 2009 2.656M
    March 31, 2009 2.429M

    About R&D Expense

    R&D expenses are a line item from many companies' income statements.

    R&D expense (short for research and development expense) is essentially the amount of money that a company spends to develop new products and services each year. For example, if a pharmaceutical firm hires research scientists to develop new drugs, the salaries of these researchers will generally be expensed in the R&D expense category.

    Like marketing expenses, but unlike capital expenditures, R&D expenses are subtracted from revenues every year directly. Therefore, accountants treat R&D spending as an expense rather than as an investment, though there is continuous debate over whether this is the correct classification.

    An investor looking at companies with large R&D expenditures should think hard about whether a single company's R&D spending is an expense (like buying rubber to produce tires) or whether it is an investment (like buying machinery to produce tires more efficiently). Determining the answer to that question can have a large impact on how the company is valued.
    Learn More

    Get data for

    HZNP R&D Expense Quarterly Benchmarks

    Companies
    Rigel Pharmaceuticals 20.32M
    Sagent Pharmaceuticals 4.261M
    Valeant Pharmaceuticals International 23.80M

    HZNP R&D Expense Quarterly Rankings

    Overall 89th percentile
    856 of 8009
    Sector 64th percentile
    245 of 687 in Healthcare
    Industry 47th percentile
    36 of 69 in Drug Manufacturers - Specialty & Generic

    HZNP R&D Expense Quarterly Range, Past 5 Years

    Minimum 2.429M Mar 2009
    Maximum 5.721M Sep 2010
    Average 3.798M